Only 5 companies have received authorization from HC for a rapid point of care covid test. These 5 companies have 8 tests combined. ALL of these tests require a blood sample or a nasopharyngeal swab except for one, which requires a less intrusive nasal swab.
NONE of them, even the first, which was authorized in October, have been able to inspire use on a mass scale. Most of that has been due to sample type, expense or the requirement of having medical professionals carry out the test.
NONE of them matches THRMs AcuVid sensitivity level of 100%.
Expectations were high that testing was completed in February ....for that reason the latest NR was a disappointment. But that doesn't negate the facts. In spite of this new narrative of hyping other stocks by bashing THRM .....those tests fill relatively small niches ....and AcuVid could fill the much larger demand and requirement.
Expectations were high (and should be). Shorters are literally surfing these boards for their next victims. Too many people expect to get rich in a week ......and the list goes on.
Morningstar's outlook has changed little with a Fair Value sp this morning of $.52 Their 1-star valuation is $3.27. Barchart has clearly responded to the NR with caution having dropped from 100% Strong Buy last month to a 56% Buy. That should be expected and provides some confidence in the analyses by both. The resistance levels are a more modest $.365, $.39 and $.405 ....those are clearly reasonable targets.
Imho this is still a stock to HOLD long. The strongest hands have stuck with it for several reasons ...it's still hard to imagine those investors can expect anything but a significant reward for their patience.